.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AB01_Busulfan.Busulfan_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AB01_Busulfan.Busulfan_1| name: | Busulfan_1 | |
| ATC code: | L01AB01_1 | route: | oral |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 0.65 | L |
| clearance: | 2.5 | ml/min/kg |
| other parameters in model implementation | ||
Busulfan is an alkylating agent that is used primarily as a chemotherapy drug for conditioning regimens prior to hematopoietic stem cell transplantation, especially in chronic myelogenous leukemia and other hematological malignancies. It is approved and in clinical use today.
Pharmacokinetic parameters reported for adult patients given oral busulfan for bone marrow transplantation.
Schiltmeyer, B, et al., & Hempel, G (2003). Population pharmacokinetics of oral busulfan in children. Cancer chemotherapy and pharmacology 52(3) 209–216. DOI:10.1007/s00280-003-0631-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/12811512
Nakamura, H, et al., & Kitada, M (2008). Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation. Therapeutic drug monitoring 30(1) 75–83. DOI:10.1097/FTD.0b013e3181621cde PUBMED:https://pubmed.ncbi.nlm.nih.gov/18223466
Hadjibabaie, M, et al., & Sadrai, S (2011). Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 19(3) 216–223. PUBMED:https://pubmed.ncbi.nlm.nih.gov/22615660